{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:13Z","timestamp":1789749493708,"version":"4.0.1"},"reference-count":17,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This phase 3 multicenter study, including 26\u2010week treatment and extension periods, evaluated the efficacy and safety of adalimumab in Japanese patients with active ulcers due to pyoderma gangrenosum. Patients received adalimumab 160\u00a0mg at week 0, 80\u00a0mg at week 2, and then 40\u00a0mg every week starting at week 4. Of the 22 enrolled patients, 12 (54.5%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) achieved the primary efficacy end\u2010point of pyoderma gangrenosum area reduction 100 (PGAR 100, defined as complete skin re\u2010epithelialization) for the target ulcer at week 26 assessed by digital planimetry. PGAR 100 response was observed as early as week 6 (13.6%) and continued to increase over time. The mean percent change from baseline in target ulcer area was \u221231.8% at week 6 and \u221263.8% at week 26. A Physician\u2019s Global Assessment score of 0 (PGA 0, all ulcers completely clear) was achieved by two patients (9.1%) at week 6 and eight (36.4%) at week 26, while PGA 0\/1 (completely\/almost clear) was achieved by five (22.7%) and 12 patients (54.5%) at week 6 and 26, respectively. Mean changes from baseline in pain numeric rating scale (\u22121.8 at week 6 and \u22122.5 at week 26) and the Dermatology Life Quality Index (\u22123.1 at week 6 and \u22123.6 at week 26) improved over time. Adverse events were reported by 18 patients, most commonly infections (<jats:italic>n<\/jats:italic>\u00a0=\u00a011), and serious adverse events by four. These results suggest that adalimumab is effective and generally well tolerated in Japanese patients with active ulcers of pyoderma gangrenosum.<\/jats:p>","DOI":"10.1111\/1346-8138.15533","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T08:20:41Z","timestamp":1598602841000},"page":"1383-1390","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty\u2010six\u2010week phase 3 open\u2010label study"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-4956","authenticated-orcid":false,"given":"Kenshi","family":"Yamasaki","sequence":"first","affiliation":[{"name":"Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3055-5202","authenticated-orcid":false,"given":"Keiichi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Department of Dermatology Graduate School of Medicine Mie University Tsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"AbbVie Inc. Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Iwano","sequence":"additional","affiliation":[{"name":"AbbVie GK Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Takei","sequence":"additional","affiliation":[{"name":"AbbVie GK Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"AbbVie GK Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-2573","authenticated-orcid":false,"given":"Toshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukushima Medical University School of Medicine Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03199.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S61202"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0251-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.021"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14658"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/11595240-000000000-00000"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-19"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2958"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-012-0006-6"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.3.306"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06467.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.2293"},{"key":"e_1_2_8_15_1","first-page":"e8","article-title":"Adalimumab therapy for recalcitrant pyoderma gangrenosum","volume":"5","author":"Fonder MA","year":"2006","journal-title":"J Burns Wounds"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.006"},{"key":"e_1_2_8_17_1","first-page":"32","article-title":"Biologics and immunoglobulins in the treatment of pyoderma gangrenosum \u2010 analysis of 52 patients","volume":"17","author":"Herberger K","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.4853"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15533","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.15533","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T14:00:24Z","timestamp":1692367224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.15533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/1346-8138.15533"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.15533","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"2020-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}